Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile

Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile
TABLE OF CONTENTS

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001–13 5

Financial performance, 2001–13 6

Takeda: PharmaVitae forecasts at a glance 7

Strategic insight 8

Prospect of blockbuster genericization prompts wave of pipeline investment 8

Follow-on therapies vital in limiting impact of generic penetration 11

SWOT analysis 13

Strengths 13

Weaknesses 15

Opportunities 16

Threats 17

CHAPTER 3 QUARTERLY NEWS UPDATE 29

Product developments 29

Deals and alliances 32

M&A activity 33

Company announcements 33

Future product milestones 34

CHAPTER 4 COMPANY INTRODUCTION 35

Key findings 35

Background 36

Key corporate developments 36

Consumer health 38

Joint ventures 39

M&A history 39

Acquisition of Millennium Pharmaceuticals 39

Acquisition of Paradigm Therapeutics 41

Acquisition of Syrrx 41

M&A strategy 42

Pharmaceuticals business unit structure 43

Prescription pharmaceuticals 43

Consumer healthcare (OTC) 43

CHAPTER 5 COMPANY SALES 44

Key findings 44

Prescription pharmaceutical sales and growth rate analysis, 2001–13 46

Historical analysis 47

Forecast analysis 48

Product analysis 49

Product analysis, 2001–07 50

Product analysis, 2007–13 54

Therapy area analysis 59

Therapy area analysis, 2001–07 61

Therapy area analysis, 2007–13 62

Therapy area focus, 2001–13 63

Geographic analysis 64

Geographic analysis, 2001–07 65

Geographic analysis, 2007–13 66

Geographic focus, 2001–13 68

Launch/core/expiry analysis 69

Explanation of launch/core/expiry analysis 69

Launch analysis, 2007–13 70

Core analysis, 2007–13 72

Expiry analysis, 2007–13 73

Launch/core/expiry configuration, 2007–13 74

Molecule type analysis 75

Molecule type analysis, 2001–07 76

Molecule type analysis, 2007–13 76

Externalization analysis 77

Externalization analysis, 2001–07 78

Externalization analysis, 2007–13 79

CHAPTER 6 COMPANY FINANCIALS 81

Key findings 81

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001–07 82

Financial statements, 2001–07 84

Profit and loss account, 2001–07 84

Balance sheet, 2001–07 85

Operating costs and profit analysis 87

Operating costs and profit analysis, 2001–07 88

Operating cost ratio and profit margin analysis, 2001–07 89

Operating cost ratio and profit margin analysis, 2007–13 90

Operating costs and profit analysis, 2007–13 92

Return on capital employed analysis 93

Capital employed analysis, 2001–07 94

Return on capital employed (RoCE) analysis, 2001–07 96

Market capitalization analysis 98

Market capitalization analysis, 2001–07 98

Total shareholder returns analysis, 2001–07 99

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 101

Key findings 101

Overview 102

Gastroenterology 103

TAK-390MR 103

Prevacid 108

Amitiza 114

Endocrine, metabolic & genetic disorders 118

Actos/ACTOplus met 118

SYR-322 125

Cardiovascular 130

Blopress/Blopress Comp 130

Oncology 137

Velcade 137

Central nervous system 142

Rozerem 142

CHAPTER 8 APPENDIX 148

R&D pipeline 148

References 150

Abbreviations 150

Exchange rates 152

TABLE OF TABLES

Table 1: Takeda – PharmaVitae forecasts at a glance 7

Table 2: Takeda key product developments, 2008 29

Table 3: Takeda deals and alliances, 2008 32

Table 5: Takeda M&A activity, Q1 2008 33

Table 6: Takeda company announcements, Q1 2008 33

Table 7: Takeda future product milestones, 2008–10 34

Table 8: Takeda product portfolio overview ($m), 2001–07 50

Table 9: Takeda product portfolio overview ($m), 2007–13 54

Table 10: Takeda product portfolio overview ($m), 2001–07 61

Table 11: Takeda product portfolio overview ($m), 2007–13 62

Table 12: Takeda portfolio overview by geographic region ($m), 2001–07 65

Table 13: Takeda portfolio overview by geographic region ($m), 2007–13 66

Table 14: Takeda launch portfolio overview ($m), 2007–13 70

Table 15: Takeda core portfolio overview ($m), 2007–13 72

Table 16: Takeda expiry portfolio overview ($m), 2007–13 73

Table 17: Takeda portfolio overview by molecule type ($m), 2001–07 76

Table 18: Takeda product portfolio overview by molecule type ($m), 2007–13 76

Table 19: Takeda product portfolio overview by source ($m), 2001–07 78

Table 20: Takeda product portfolio overview by source ($m), 2007–13 79

Table 21: Total Takeda sales by business unit ($m), 2001–07 82

Table 22: Takeda profit and loss account ($m), 2001–07 84

Table 23: Takeda balance sheet ($m), 2001–07 85

Table 24: Takeda operating revenue/cost analysis ($m), 2001–07 88

Table 25: Takeda operating cost ratio analysis (% of total revenues), 2001–07 89

Table 26: Takeda operating cost ratio analysis (% of total revenues), 2007–13 90

Table 27: Takeda operating revenue/cost analysis ($m), 2007–13 92

Table 28: Takeda capital employed ($m), 2001–07 94

Table 29: Takeda EBIT return on capital employed ($m), 2001-07 96

Table 30: Takeda EBIT pre-tax return/Capital employed driver analysis (%), 2001–07 96

Table 31: Takeda market capitalization ($ billion), 2001–07 98

Table 34: Takeda total shareholder returns (annual %), 2001–07 99

Table 33: Key products overview 102

Table 34: TAK-390MR: overview 104

Table 35: TAK-390MR: sales forecast ($m), 2007–13 105

Table 34: Prevacid: overview 109

Table 35: Prevacid: sales forecast ($m), 2007–13 110

Table 34: Amitiza: overview 115

Table 35: Amitiza: sales forecast ($m), 2007–13 116

Table 34: Actos: overview 119

Table 34: ACTOplus met: overview 120

Table 35: Actos: sales forecast ($m), 2007–13 121

Table 35: ACTOplus met: sales forecast ($m), 2007–13 121

Table 34: SYR-322: overview 126

Table 35: SYR-322: sales forecast ($m), 2007–13 127

Table 34: Blopress: overview 131

Table 34: Blopress Comp: overview 132

Table 35: Blopress: sales forecast ($m), 2007–13 133

Table 35: Blopress Comp: sales forecast ($m), 2007–13 133

Table 34: Velcade: overview 138

Table 35: Velcade: sales forecast ($m), 2007–13 139

Table 34: Rozerem: overview 143

Table 35: Rozerem: sales forecast ($m), 2007–13 144

Table 56: Takeda’s R&D pipeline (Phase I–registration) 148

Table 38: Exchange rates, 2007 152

TABLE OF FIGURES

Figure 1: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 5

Figure 2: Takeda’s financial performance ($m), 2001–13 6

Figure 3: Takeda SWOT analysis 13

Figure 7: Pharmaceuticals business unit structure 43

Figure 8: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001–13 47

Figure 9: Takeda key sales growth driver & resistors ($m), 2001–07 51

Figure 10: Takeda key sales growth drivers & resistors ($m), 2007–13 55

Figure 11: Takeda prescription pharmaceutical sales by therapy area ($m), 2001–13 60

Figure 12: Takeda prescription pharma sales by therapy area (% of total), 2001–13 63

Figure 13: Takeda prescription pharmaceutical sales by geographic region ($m), 2001–13 64

Figure 15: Takeda drivers and resistors by geographic region ($m), 2007–13 66

Figure 16: Takeda prescription pharmaceutical sales by geographic region (% of total), 2001–13 68

Figure 17: Takeda launch/core/expiry configuration ($m), 2007–13 74

Figure 18: Takeda prescription pharmaceutical sales by molecule type ($m), 2001–13 75

Figure 20: Takeda prescription pharmaceutical sales by source ($m), 2001–13 77

Figure 22: Takeda growth drivers and resistors by source ($m), 2007–13 79

Figure 23: Takeda operating revenue/cost analysis ($m), 2001–13 87

Figure 24: Takeda operating cost ratio analysis (% of total revenues), 2001–13 91

Figure 25: Takeda return on capital employed, EBIT margin and capital turnover, 2001–07 93

Figure 26: Return on capital employed formula 97

Figure 27: Takeda market capitalization ($ billion), 2001–07 99

Figure 28: Takeda total shareholder returns vs. S&P 500 ($m), 2001–07 100

Figure 27: Takeda’s upper GI franchise, sales ($m), 2007–13 107